|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0150 USD | +7,400.00% |
|
+14,900.00% | +4,900.00% |
| 20/06/24 | Vaxxinity UB-312 Parkinson?s Trial Results Published in Nature Medicine | CI |
| 12/05/24 | Vaxxinity, Inc.(OTCPK:VAXX) dropped from S&P Global BMI Index | CI |
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
Profitability | |||||
Return on Assets | - | -78 | -72.11 | -34.78 | -48.34 |
Return on Total Capital | - | -667.42 | -102.38 | -43.96 | -69.19 |
Return On Equity % | - | 171.52 | -264.51 | -78.85 | -150.65 |
Return on Common Equity | - | 58.81 | -665.19 | -78.85 | -150.65 |
Margin Analysis | |||||
Gross Profit Margin % | - | 90.66 | -2.83K | - | - |
SG&A Margin | - | 2.19K | 78.52K | - | - |
EBITDA Margin % | - | -5.67K | -188K | - | - |
EBITA Margin % | - | -5.8K | -190K | - | - |
EBIT Margin % | - | -5.8K | -190K | - | - |
Income From Continuing Operations Margin % | - | -7.17K | -208K | - | - |
Net Income Margin % | - | -7.17K | -208K | - | - |
Net Avail. For Common Margin % | - | -7.17K | -208K | - | - |
Normalized Net Income Margin | - | -4.48K | -130K | - | - |
Levered Free Cash Flow Margin | - | -3.8K | -50.35K | - | - |
Unlevered Free Cash Flow Margin | - | -3.69K | -49.95K | - | - |
Asset Turnover | |||||
Asset Turnover | - | 0.02 | 0 | - | - |
Fixed Assets Turnover | - | 0.09 | 0.01 | - | - |
Inventory Turnover (Average Inventory) | - | - | 0.52 | - | - |
Short Term Liquidity | |||||
Current Ratio | 0.07 | 0.96 | 5.61 | 3.03 | 1.89 |
Quick Ratio | 0.04 | 0.85 | 5.44 | 2.84 | 1.76 |
Operating Cash Flow to Current Liabilities | -0.62 | -0.91 | -2.95 | -1.81 | -3.25 |
Days Outstanding Inventory (Average Inventory) | - | - | 700.32 | - | - |
Average Days Payable Outstanding | - | - | 277.71 | - | - |
Long Term Solvency | |||||
Total Debt/Equity | -66.08 | -153.84 | 8.32 | 23.4 | 113.12 |
Total Debt / Total Capital | -194.78 | 285.75 | 7.68 | 18.96 | 53.08 |
LT Debt/Equity | -5.3 | -43.02 | 8.03 | 20.98 | 98.9 |
Long-Term Debt / Total Capital | -15.61 | 79.91 | 7.41 | 17 | 46.41 |
Total Liabilities / Total Assets | 1.46K | 149.66 | 22.83 | 41.56 | 69.74 |
EBIT / Interest Expense | -31.4 | -27.33 | -148.9 | -147.82 | -83.74 |
EBITDA / Interest Expense | -30.7 | -25.97 | -147.59 | -144.54 | -80.53 |
(EBITDA - Capex) / Interest Expense | -30.7 | -27.22 | -149.16 | -148.17 | -81.69 |
Total Debt / EBITDA | -1.07 | -1.25 | -0.09 | -0.2 | -0.27 |
Net Debt / EBITDA | -1.04 | -0.23 | 1.12 | 0.98 | 0.28 |
Total Debt / (EBITDA - Capex) | -1.07 | -1.19 | -0.09 | -0.19 | -0.27 |
Net Debt / (EBITDA - Capex) | -1.04 | -0.22 | 1.11 | 0.95 | 0.27 |
Growth Over Prior Year | |||||
Total Revenues, 1 Yr. Growth % | - | - | -88.15 | - | - |
Gross Profit, 1 Yr. Growth % | - | - | -470.5 | - | - |
EBITDA, 1 Yr. Growth % | - | 132.88 | 292.75 | -40.07 | -24.56 |
EBITA, 1 Yr. Growth % | - | 136.31 | 287.44 | -39.25 | -23.29 |
EBIT, 1 Yr. Growth % | - | 136.31 | 287.44 | -39.25 | -23.29 |
Earnings From Cont. Operations, 1 Yr. Growth % | - | 181.01 | 243.31 | -45.16 | -24.31 |
Net Income, 1 Yr. Growth % | - | 181.01 | 243.31 | -45.16 | -24.31 |
Normalized Net Income, 1 Yr. Growth % | - | 182.12 | 243.31 | -44.08 | -24.31 |
Diluted EPS Before Extra, 1 Yr. Growth % | - | 46.46 | 194.23 | -66.65 | -24.65 |
Inventory, 1 Yr. Growth % | - | - | 25.11 | -92.95 | - |
Net Property, Plant and Equip., 1 Yr. Growth % | - | 7.5K | 0.12 | 1.13 | -11.44 |
Total Assets, 1 Yr. Growth % | - | 3.04K | 232.41 | -36.16 | -58.35 |
Tangible Book Value, 1 Yr. Growth % | - | 80.11 | -247.2 | -51.66 | -78.43 |
Common Equity, 1 Yr. Growth % | - | 80.11 | -247.2 | -51.66 | -78.43 |
Cash From Operations, 1 Yr. Growth % | - | 176.48 | 138.84 | -30.94 | 2.34 |
Capital Expenditures, 1 Yr. Growth % | - | - | -10.77 | 41.58 | -56.97 |
Levered Free Cash Flow, 1 Yr. Growth % | - | - | 74.53 | -4.68 | 6.23 |
Unlevered Free Cash Flow, 1 Yr. Growth % | - | - | 79.08 | -4.73 | 5.95 |
Compound Annual Growth Rate Over Two Years | |||||
EBITDA, 2 Yr. CAGR % | - | - | 202.43 | 53.42 | -32.76 |
EBITA, 2 Yr. CAGR % | - | - | 202.58 | 53.41 | -31.74 |
EBIT, 2 Yr. CAGR % | - | - | 202.58 | 53.41 | -31.74 |
Earnings From Cont. Operations, 2 Yr. CAGR % | - | - | 210.6 | 37.21 | -35.58 |
Net Income, 2 Yr. CAGR % | - | - | 210.6 | 37.21 | -35.58 |
Normalized Net Income, 2 Yr. CAGR % | - | - | 211.21 | 37.21 | -34.94 |
Diluted EPS Before Extra, 2 Yr. CAGR % | - | - | 107.59 | -0.95 | -49.87 |
Inventory, 2 Yr. CAGR % | - | - | - | -72.59 | - |
Net Property, Plant and Equip., 2 Yr. CAGR % | - | - | 772.25 | 1.45 | -5.36 |
Total Assets, 2 Yr. CAGR % | - | - | 922.24 | 45.67 | -48.44 |
Tangible Book Value, 2 Yr. CAGR % | - | - | 62.83 | -15.64 | -67.71 |
Common Equity, 2 Yr. CAGR % | - | - | 62.83 | -15.64 | -67.71 |
Cash From Operations, 2 Yr. CAGR % | - | - | 156.97 | 28.43 | -15.93 |
Capital Expenditures, 2 Yr. CAGR % | - | - | - | 12.4 | -21.95 |
Levered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 35.94 | 0.63 |
Unlevered Free Cash Flow, 2 Yr. CAGR % | - | - | - | 37.72 | 0.47 |
Compound Annual Growth Rate Over Three Years | |||||
EBITDA, 3 Yr. CAGR % | - | - | - | 76.32 | 21.09 |
EBITA, 3 Yr. CAGR % | - | - | - | 77.18 | 21.77 |
EBIT, 3 Yr. CAGR % | - | - | - | 77.18 | 21.77 |
Earnings From Cont. Operations, 3 Yr. CAGR % | - | - | - | 74.24 | 12.53 |
Net Income, 3 Yr. CAGR % | - | - | - | 74.24 | 12.53 |
Normalized Net Income, 3 Yr. CAGR % | - | - | - | 74.47 | 12.53 |
Diluted EPS Before Extra, 3 Yr. CAGR % | - | - | - | 12.85 | -9.58 |
Net Property, Plant and Equip., 3 Yr. CAGR % | - | - | - | 327.63 | -3.04 |
Total Assets, 3 Yr. CAGR % | - | - | - | 305.56 | -4.04 |
Tangible Book Value, 3 Yr. CAGR % | - | - | - | 8.62 | -46.46 |
Common Equity, 3 Yr. CAGR % | - | - | - | 8.62 | -46.46 |
Cash From Operations, 3 Yr. CAGR % | - | - | - | 65.83 | 19.07 |
Capital Expenditures, 3 Yr. CAGR % | - | - | - | - | -18.38 |
Levered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 25.21 |
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | - | - | - | 26.19 |
- Stock Market
- Stocks
- VAXX Stock
- Financials Vaxxinity, Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















